Related Experiment Video
Updated: Jul 14, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
TGF-beta(1) gene polymorphism in psoriasis vulgaris
Wojciech Baran1, Jacek C Szepietowski, Grzegorz Mazur
1Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Chalubinskiego 1, 50-368 Wroclaw, Poland. wbaran@derm.am.wroc.pl
Cytokine
|June 15, 2007
Summary
Transforming growth factor-beta 1 (TGF-beta(1)) gene polymorphisms are not linked to psoriasis vulgaris susceptibility. However, specific TGF-beta(1) genotypes may influence disease type, differentiating early-onset from late-onset psoriasis.
Area of Science:
- Immunogenetics
- Dermatology
- Molecular Biology
Background:
- Transforming growth factor-beta 1 (TGF-beta(1)) overexpression is linked to inflammatory diseases like psoriasis.
- Single nucleotide polymorphisms (SNPs) in TGF-beta(1) may influence disease susceptibility and progression.
Purpose of the Study:
- To investigate the association between TGF-beta(1) gene polymorphisms and psoriasis vulgaris susceptibility.
- To determine if specific TGF-beta(1) genotypes correlate with early-onset (Type I) versus late-onset (Type II) psoriasis.
Main Methods:
- Genotyping of TGF-beta(1) gene polymorphisms at codon 10 (T/C) and codon 25 (G/C) using PCR-SSP.
- Comparison of genotype frequencies between 78 psoriasis vulgaris patients and 74 healthy controls.
- Subgroup analysis comparing Type I and Type II psoriasis patients.
Main Results:
- No significant difference in TGF-beta(1) genotype frequencies was observed between psoriasis patients and healthy controls.
- A highly significant difference in genotype frequencies was found between Type I and Type II psoriasis patients (p <0.0003).
- Specific genotypes (CC/GG, TC/GG) were more frequent in Type I, while TT/GG was more common in Type II psoriasis.
Conclusions:
- TGF-beta(1) gene polymorphism at codons 10 and 25 is not associated with susceptibility to psoriasis vulgaris.
- These TGF-beta(1) polymorphisms may play a role in determining the clinical type of psoriasis, particularly the onset of the disease.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:33Pleiotropy
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...